pharmaphorum | News & views on pharma and biotech’s evolving …
pharmaphorum is an online publication seeking to educate, inform, engage, & connect pharmaceutical industry leaders to thrive in healthcare’s evolving future.
FDA sets August date for subcutaneous Leqembi decision
2 hours ago · The FDA has started its review of a subcutaneous injection formulation of Eisai and Biogen's Alzheimer's drug Leqembi that could allow patients to receive maintenance doses at …
Delivering for patients and sites in 2025 | pharmaphorum
Dec 18, 2024 · Discover how clinical trials are evolving to prioritise patient needs and streamline processes for sites in 2025.
News | Timely industry updates for pharma and biotech leaders
1 day ago · pharmaphorum’s news coverage updates daily with the latest pharma and biotech stories, from funding and M&A to regulatory approvals and policy shifts.
11 blockbuster drugs to look out for in 2025 | pharmaphorum
6 days ago · Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.
pharmaphorum - The Deep Dive Digital Magazine has fresh …
Feb 28, 2024 · Digital Health 2023. 29-11-2023 Deep Dive – Digital Health 2023 features interviews, analysis, and commentary from pharmaphorum, Lumanity, AXON, Viseven, …
Life Sciences Industry Report 2025 PART 1 | pharmaphorum
4 days ago · In pharmaphorum’s inaugural Life Sciences Industry Report 2025, delve into the trends that propelled the pharmaceutical industry along in 2024.
Verona says COPD drug is off to a flying start | pharmaphorum
6 days ago · Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is …
About pharmaphorum
3 days ago · pharmaphorum.com is a leading online destination for healthcare and pharmaceutical industry news, insight, and debate – as is its associated digital magazine Deep …
Pharma | pharmaphorum
Unlocking impact and growth at times of demerger. Pharma and medtech companies have undergone unprecedented growth through aggressive M&A over the